A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 12 Apr 2018 Planned initiation date changed from 31 Mar 2018 to 31 Jul 2018.
- 12 Feb 2018 New trial record